International Journal of Innovative Technologies in Social Science

e-ISSN: 2544-9435

Operating Publisher
SciFormat Publishing Inc.
ISNI: 0000 0005 1449 8214

2734 17 Avenue SW,
Calgary, Alberta, T3E0A7,
Canada
+15878858911
editorial-office@sciformat.ca

ARTICLE TITLE	EMERGING THERAPEUTIC AND DIGITAL INNOVATIONS IN CYSTIC FIBROSIS: A COMPREHENSIVE REVIEW
DOI	https://doi.org/10.31435/ijitss.1(49).2026.4912
RECEIVED	19 December 2025
ACCEPTED	27 February 2026
PUBLISHED	14 March 2026
LICENSE	The article is licensed under a **Creative Commons Attribution 4.0 International License.**

EMERGING THERAPEUTIC AND DIGITAL INNOVATIONS IN CYSTIC FIBROSIS: A COMPREHENSIVE REVIEW

Gabriela Mroczka *(Corresponding Author, Email: gabrielamroczka1@gmail.com)*
National Medical Institute of the Ministry of the Interior and Administration in Rzeszów, Rzeszów, Poland
ORCID ID: 0009-0008-6382-3123

Paulina Łobaza
Medical Center in Łańcut Sp. z o.o., Łańcut, Poland
ORCID ID: 0009-0003-3566-005X

Idalia Myszor
University Clinical Hospital F. Chopin in Rzeszów, Rzeszów, Poland
ORCID ID: 0009-0008-5365-7037

Michał Madej
University Clinical Hospital F. Chopin in Rzeszów, Rzeszów, Poland
ORCID ID: 0009-0009-3411-2178

Maria Kubacka
Saint Queen Jadwiga Clinical Regional Hospital No. 2 in Rzeszów, Rzeszów, Poland
ORCID ID: 0000-0002-0789-5201

Lucjan Kocemba
University Clinical Hospital F. Chopin in Rzeszów, Rzeszów, Poland
ORCID ID: 0009-0006-0441-9927

Sylwia Nycz-Jucha
Medical Center in Łańcut Sp. z o.o., Łańcut, Poland
ORCID ID: 0009-0004-9042-2449

Brygida Pinkowicz
Medical Center in Łańcut Sp. z o.o., Łańcut, Poland
ORCID ID: 0009-0003-3290-7109

Piotr Rachwał
University Clinical Hospital F. Chopin in Rzeszów, Rzeszów, Poland
ORCID ID: 0009-0005-1434-1433

Barbara Nowak-Misiąg
Medical Center in Łańcut Sp. z o.o., Łańcut, Poland
ORCID ID: 0009-0000-9466-3443

ABSTRACT

Cystic fibrosis (CF) is an autosomal recessive, multisystem genetic disorder caused by mutations in the CFTR gene, leading to defective chloride transport across epithelial surfaces. Historically associated with early mortality, CF care has transformed over the last decade due to CFTR modulator therapies that target the underlying protein defect, significantly improving pulmonary function, reducing exacerbations, and enhancing quality of life. Concurrently, digital health technologies such as telemedicine, remote monitoring, artificial intelligence (AI) facilitated predictive tools, and wearable sensors are reshaping care delivery. Additionally, advances in gene therapy and personalized medicine hold potential for future curative approaches. This review synthesizes current evidence on CFTR modulators, emerging therapeutic strategies, the integration of digital health in CF care, and the psychosocial and economic challenges that persist. We provide a holistic perspective on how these developments collectively advance CF management, and we highlight ongoing research directions to further improve outcomes.

KEYWORDS

Cystic Fibrosis, CFTR Modulators, Gene Therapy, Digital Health, Quality of Life

CITATION

Gabriela Mroczka, Paulina Łobaza, Idalia Myszor, Michał Madej, Maria Kubacka, Lucjan Kocemba, Sylwia Nycz-Jucha, Brygida Pinkowicz, Piotr Rachwał, Barbara Nowak-Misiąg. (2026) Emerging Therapeutic and Digital Innovations in Cystic Fibrosis: A Comprehensive Review. *International Journal of Innovative Technologies in Social Science*. 1(49). doi: 10.31435/ijitss.1(49).2026.4912

Introduction

Cystic fibrosis is a life-shortening genetic disorder caused by mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene, which encodes a chloride channel essential for ion and water transport across epithelial surfaces. Dysfunctional CFTR leads to thickened secretions, predisposing patients to chronic pulmonary infections, bronchiectasis, pancreatic insufficiency, liver disease, and complications in multiple organ systems. Historically, CF management focused on supportive therapies, including chest physiotherapy, antibiotics, mucolytics, and nutritional support, which modestly improved survival but did not address the fundamental defect. The median age of survival has increased gradually, but marked changes have occurred only with the advent of targeted therapies addressing CFTR dysfunction.

The past decade has seen transformative therapies aimed at restoring or improving CFTR function with modulators such as ivacaftor, lumacaftor/ivacaftor, and, most effectively, elexacaftor/tezacaftor/ivacaftor (ETI) [1,2]. Concurrently, telemedicine and remote monitoring technologies have enabled more continuous and patient-centered care. Personalized medicine — including genomic diagnostics and biomarker development — is refining individualized treatment regimens [3]. Emerging technologies, including AI for predictive analytics and gene-targeted approaches, promise further refinements in CF management.

This review provides an integrated overview of therapeutic advances in CF, combining clinical evidence with innovations in digital health, predictive tools, gene therapy research, and the psychosocial and economic considerations that accompany this evolving landscape.

CFTR Modulator Therapies and Clinical Outcomes

The development of CFTR modulators represents a fundamental shift from symptom-focused therapy to precision medicine in CF. Ivacaftor, the first approved CFTR potentiator, increases channel gating and function in select mutations, while correctors such as tezacaftor and elexacaftor improve protein folding and trafficking to the cell surface. The triple-combination regimen ETI has emerged as the most broadly effective to date, benefiting patients with at least one copy of the common F508del mutation or other responsive genotypes [1,2].

Registry-based real-world evidence confirms the transformative impact of these therapies. A study conducted in a Polish CF population of adult patients treated with modulators documented a **marked reduction in hospitalizations due to severe exacerbations** — from 1.25 to 0.21 per patient per year — after one year of treatment, accompanied by a **66% reduction in ambulatory exacerbations** and significant improvements in spirometry measures including median FEV_1% and FVC% [1]. These findings align with other observational studies demonstrating improved pulmonary function, reduced exacerbation frequency, and enhanced nutritional indices among patients receiving ETI and other modulator regimens [4,5].

Longitudinal and registry data further suggest that widespread use of CFTR modulators has accelerated improvements in survival. A secondary analysis of the United States Cystic Fibrosis Foundation Patient Registry showed that median survival age increased from approximately 29 years in 1990 to 68 years by 2023, with the most rapid gains observed after the introduction of ETI in 2019 [5]. This evidence supports the assertion that targeted CFTR modulation has had a profound impact on the natural history of CF.

Advances in understanding the molecular and cellular effects of CFTR modulators also shed light on their broader physiological impact. Transcriptomic studies found that ETI therapy led to rapid downregulation of neutrophilic inflammatory gene expression, improved epithelial differentiation and barrier function, and decreased relative abundance of pathogenic bacteria such as Pseudomonas over time [2]. Additionally, changes in the airway and gut microbiome following ETI initiation have been documented, reflecting improved host physiology and decreased reliance on systemic antibiotics [2,6].

Despite these advances, variable responses to modulators persist across patient subgroups due to differences in mutation class, baseline disease severity, and comorbid conditions. Moreover, a small proportion of people with CF remain ineligible for current CFTR modulators due to genotypes not yet responsive to available therapies [2].

Diagnostics and Personalized Medicine

Personalized medicine in CF begins with precise genetic diagnostics. CFTR mutations are classified into functional categories based on the underlying defect, including protein production, processing, gating, and conductance. Molecular diagnostic techniques such as next-generation sequencing and sweat chloride testing are standard components of CF diagnosis and help guide therapeutic decisions. Emerging biomarkers — including multi-omics profiles and organoid functional assays — aim to refine individualized treatment further by predicting modulator responsiveness and disease trajectory [6].

Personalized approaches also extend to assessments of disease progression and response to therapy. Biomarker changes such as reductions in sweat chloride concentration correlate with restored CFTR activity and clinical improvement, while measures of nasal potential difference and intestinal current are promising tools for functional evaluation of CFTR modulation. Such precision diagnostics allow clinicians to optimize therapeutic regimens and monitor outcomes more effectively.

Gene Therapy and Molecular Correction Approaches

Gene therapy holds promise as a curative strategy for CF by aiming to replace or repair defective CFTR genes. Decades of research have explored both viral and non-viral delivery systems to introduce functional CFTR sequences into airway epithelial cells. Preclinical studies using lentiviral vectors have shown long-term phenotype correction and increased chloride transport in animal models, although first-in-human trials remain limited [8].

Non-viral gene delivery methods, such as liposomal vectors and nanoparticle-mediated delivery of chemically modified CFTR mRNA, have demonstrated potential to enhance protein expression and chloride channel function in vitro, but achieving efficient and sustained gene expression in vivo remains a significant challenge [8].

Gene editing techniques such as CRISPR/Cas9 and prime editing are under investigation to correct specific mutations at the genomic level. Translation of these approaches into safe and effective clinical therapies is still in early stages, with ongoing work needed to overcome delivery, off-target effects, and regulatory hurdles [8].

Telemedicine and Digital Health Integration

Telemedicine has become an integral component of CF care, particularly since the COVID-19 pandemic. Remote consultations and monitoring enable more flexible care delivery, reduce the burden of frequent clinic visits, and decrease infection risks associated with hospital visits. Platforms facilitating remote spirometry, symptom logging, and adherence tracking offer clinicians greater visibility into patient health and allow for timelier interventions [3,7].

Digital health platforms support treatment adherence, enable early identification of pulmonary exacerbations, and facilitate psychological support. Limitations include absence of in-person examinations and challenges in microbiological surveillance when sputum samples are not collected in clinic [3,7]. Hybrid care models that integrate telehealth with periodic in-person assessments are considered optimal for chronic CF management.

AI, Wearables, and Predictive Analytics

Advanced digital technologies, including artificial intelligence (AI) and wearable devices, are emerging tools for predictive analytics and patient monitoring in CF. AI-assisted home monitoring systems can detect pulmonary exacerbations using respiratory sound patterns and physiological signals. In studies, AI-assisted devices demonstrated notable sensitivity and specificity in identifying exacerbations in self-recorded assessments [9].

Wearable sensors and mobile health applications offer continuous monitoring of activity, respiratory parameters, and treatment adherence. Qualitative studies report optimism among patients and care teams, while highlighting concerns about data accuracy, patient anxiety, and the need for validated clinical outcomes [9].

These tools are not yet standard of care, but research suggests they may complement traditional assessments and support proactive management.

Psychosocial Impact and Quality of Life

Improvements in clinical outcomes through CFTR modulators have been accompanied by meaningful enhancements in quality of life. Patients report reduced symptom burden, improved physical functioning, and decreased anxiety and depression scores [2,6].

Longer life expectancy introduces new psychosocial challenges. Adults living longer with CF face complex decisions related to careers, family planning, and chronic disease management. Digital platforms can facilitate access to mental health services, peer support, and behavioral interventions, complementing medical therapy.

Costs, Access, and Equity Challenges

Despite dramatic clinical advances, disparities in access to CF therapies persist. Highly effective CFTR modulators, especially triple combinations, are among the most expensive medications worldwide. Efforts to improve affordability, including generics, can broaden access, but regulatory and policy barriers remain [1,5].

High drug costs strain healthcare budgets in high-income countries and raise questions about cost-effectiveness. Equitable access to diagnostics, monitoring, and emerging therapies requires collaboration among clinicians, patient advocacy groups, policymakers, and industry stakeholders.

Discussion

The landscape of CF care has evolved dramatically with CFTR modulators that directly address the molecular defect, leading to improved outcomes and extended survival. Real-world evidence demonstrates reduced exacerbations, improved lung function, and enhanced quality of life. Telemedicine and digital monitoring provide continuity of care, while AI and wearables offer promising predictive capabilities, though long-term benefit data are still accruing.

Gene therapy remains a compelling but unrealized curative goal, with ongoing research focused on vectors and gene-editing strategies. Personalized medicine through advanced diagnostics continues to refine therapy selection. Psychosocial considerations and economic inequities remain critical for ensuring that advances translate into improved outcomes for all people with CF.

Conclusions

Cystic fibrosis management is in a transformative era driven by targeted CFTR modulators and digital health innovations. Real-world evidence confirms substantial clinical benefits, while telemedicine and predictive tools expand care beyond traditional settings. Personalized medicine and gene-targeted approaches hold future promise. Addressing psychosocial and access challenges is essential to ensure equitable health outcomes. Continued research, policy efforts, and multidisciplinary collaboration are fundamental for sustaining progress in CF care.

REFERENCES

1. Winiarska, H. M., Springer, D., Wojtaś, F., Wysocka, E., & Cofta, S. (2024). CFTR modulators therapy efficacy in reducing cystic fibrosis (CF) exacerbation and improving selected spirometry parameters: A real-life study in a single-centre Polish population. *Journal of Clinical Medicine, 13*(15), Article 4491. https://doi.org/10.3390/jcm13154491
2. Regard, L., Martin, C., Burnet, E., Da Silva, J., & Burgel, P.-R. (2022). CFTR modulators in people with cystic fibrosis: Real-world evidence in France. *Cells, 11*(11), Article 1769. https://doi.org/10.3390/cells11111769
3. Fainardi, V., Capoferri, G., Tornesello, M., Pisi, G., & Esposito, S. (2023). Telemedicine and its application in cystic fibrosis. *Journal of Personalized Medicine, 13*(7), Article 1041. https://doi.org/10.3390/jpm13071041
4. Gramegna, A., Contarini, M., Aliberti, S., Casciaro, R., Blasi, F., & Castellani, C. (2020). From ivacaftor to triple combination: A systematic review of efficacy and safety of CFTR modulators in people with cystic fibrosis. *International Journal of Molecular Sciences, 21*(16), Article 5882. https://doi.org/10.3390/ijms21165882
5. Pastor-Vivero, M. D., Costa i Colomer, J., Martín de Vicente, C., Vicente-Santamaría, S., García Romero, R., González Jiménez, D., & Luna Paredes, C. (2025). Advances in the treatment of cystic fibrosis: CFTR modulators. *Anales de Pediatría (English Edition), 102*(5), Article 503857. https://doi.org/10.1016/j.anpede.2025.503857
6. Tümmler, B., Pallenberg, S. T., Dittrich, A. M., Graeber, S. Y., Naehrlich, L., Sommerburg, O., & Mall, M. A. (2025). Progress of personalized medicine of cystic fibrosis in the times of efficient CFTR modulators. *Molecular and Cellular Pediatrics, 12*(1), Article 6. https://doi.org/10.1186/s40348-025-00194-0
7. Vagg, T., Shanthikumar, S., Morrissy, D., Chapman, W. W., Plant, B. J., & Ranganathan, S. (2021). Telehealth and virtual health monitoring in cystic fibrosis. *Current Opinion in Pulmonary Medicine, 27*(6), 544–553. https://doi.org/10.1097/MCP.0000000000000821
8. Lomunova, M. A., & Gershovich, P. M. (2023). Gene therapy for cystic fibrosis: Recent advances and future prospects. *Acta Naturae, 15*(2), 20–31. https://doi.org/10.32607/actanaturae.11708
9. Mazurek, H., Emeryk, A., Janeczek, K., Derom, E., Kuźnar-Kamińska, B., Grzywalski, T., Biniakowski, A., Szarzyński, K., Pastusiak, A., Kaminiarczyk-Pyzałka, D., Botteldooren, D., Hafke-Dys, H., & Kociński, J. (2025). AI-facilitated home monitoring for cystic fibrosis exacerbations across pediatric and adult populations. *Journal of Cystic Fibrosis, 24*(2), 390–397. https://doi.org/10.1016/j.jcf.2025.02.011